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ABSTRACT
Objective To determine the risk of colorectal cancer after
screening with flexible sigmoidoscopy.
Design Randomised controlled trial.
Setting Population based screening in two areas in
Norway—city of Oslo and Telemark county (urban and
mixed urban and rural populations).
Participants 55736 men and women aged 55-64 years.
Intervention Once only flexible sigmoidoscopy screening
with or without a single round of faecal occult blood
testing (n=13823) compared with no screening (n=
41913).
Main outcome measures Planned end points were
cumulative incidence and mortality of colorectal cancer
after 5, 10, and 15 years. This first report from the study
presents cumulative incidence after 7 years of follow-up
and hazard ratio for mortality after 6 years.
Results No difference was found in the 7 year cumulative
incidenceof colorectalcancerbetweenthe screeningand
control groups (134.5 v 131.9 cases per 100000 person
years). In intention to screen analysis, a trend towards
reduced colorectal cancer mortality was found (hazard
ratio0.73,95%confidenceinterval0.47to1.13,P=0.16).
For attenders compared with controls, a statistically
significant reduction in mortality was apparent for both
total colorectal cancer (hazard ratio 0.41, 0.21 to 0.82,
P=0.011) and rectosigmoidal cancer (0.24, 0.08 to 0.76,
P=0.016).
Conclusions A reduction in incidence of colorectal cancer
with flexible sigmoidoscopy screening could not be
shown after 7 years’ follow-up. Mortality from colorectal
cancer was not significantly reduced in the screening
group but seemed to be lower for attenders, with a
reductionof59%foranylocationofcolorectalcancerand
76%forrectosigmoidalcancerinperprotocolanalysis,an
analysis prone to selection bias.
Trial registration Clinical trials NCT00119912.
INTRODUCTION
More than 500000 estimated annual deaths from col-
orectaladenocarcinomamakethisthethirdmostcom-
mon cause of deaths from cancer worldwide.
1
Symptoms tend to appear late in the course of the dis-
ease, and early surgery remains the only option for
cure. For the past decade, screening for colorectal can-
cer with flexible endoscopes has therefore been advo-
catedintheUnitedStates.
2SeveralEuropeancountries
have recently launched large scale colonoscopy
screening programmes for the general population.
34
Evidenceshowsthat endoscopicscreening maypre-
ventcolorectalcancerbydetectionandremovalofpre-
malignant, adenomatous polyps.
5-7 This effect might,
however, have been overestimated, as the extent of
spontaneous regression of adenomas is largely
unknown.
8 Apart from a small scale trial on screening
with flexible sigmoidoscopy, none of these studies
investigating screening and polypectomy have been
randomised trials.
9 The World Health Organization
recommends that screening programmes should be
set up only when their effectiveness has been
demonstrated.
10 The United Kingdom National
Screening Committee explicitly demands that this is
based on randomised trials.
11 The NORwegian Color-
ectal CAncer Prevention (NORCCAP) trial 1 is a
population based randomised controlled trial for the
prevention of colorectal cancer, comparing once only
flexible sigmoidoscopy with no screening (usual care).
The primary end point of the study is incidence of col-
orectalcancer,whichwastobereportedafter5,10,and
15 years of follow-up.
ThispaperpresentsthefirstresultsfromtheNORC-
CAPtrial1ontheincidenceofcolorectalcanceraftera
minimumofsix(rangesixtoeight)yearsandmortality
from colorectal cancer after a minimum of five (five to
seven) years of follow-up. It is, to our knowledge, the
first report to present data on the effect of screening
withflexiblesigmoidoscopyfroma largescalepopula-
tion based randomised controlled trial.
METHODS
Population and participants
Norway has a unique person identification system,
which uses a compulsory 11 digit identification num-
ber (including date of birth) for each person living in
Norway;thissecuresregistrationoflifetimeeventsand
longitudinal data for epidemiological research. All
residents aged 55-64 years living in the city of Oslo
and Telemark County, Norway, who were registered
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November 1998 (n=55736), were eligible for the
NORCCAP trial 1. Of these, 13823 people (men and
women, 1:1) were drawn by individual randomisation
from the population registry and invited directly to
once only flexible sigmoidoscopy screening (one step
invitation procedure); this process mimicked invita-
tion procedures for national screening programmes.
12
An independent body (Statistics Norway) did the ran-
domisations. Fifty per cent of those invited (6908
people, 1:1 randomisation within the screening
group) were also asked to provide three consecutive
stool samples on attendance for screening, to investi-
gate the effect on compliance of adding a supplemen-
tary screening modality (faecal occult blood) with
additionalinconvenience forpeoplescreened.Screen-
ing for occult blood only was not an option.
People randomised to the control group (n=41913)
were not offered any screening; they were not con-
tacted, and follow-up was purely registry based. To
obtainawideragerangeforfuturedecisionsonscreen-
ing policy in Norway, we decided towards the end of
the study period to include an additional randomised
sample of the population at age 50-54 years to be
offeredflexiblesigmoidoscopyonlyorcombinedflex-
ible sigmoidoscopy and faecal occult blood testing.
Owing to short follow-up, data from this add-on
study group will not be presented here.
Screening intervention
Screeningexaminationswere doneat twocentres (one
in each of the screening areas) between January 1999
and December 2000. Bowel preparation for flexible
sigmoidoscopy was restricted to a 240 ml sorbitol
enema administered at the screening centre on atten-
dance. Ordinary colonoscopes were used both for
flexible sigmoidoscopy screening and work-up colo-
noscopyforscreenpositives(140cmOlympuscolono-
scopes, Olympus Europa GmbH, Hamburg,
Germany). The level reached was measured in centi-
metres from the anal verge with the endoscope in a
straightened position, as judged by the endoscopist. A
temporary satellite screening unit was set up for the
inhabitants of the most peripheral parts of rural Tele-
mark county, staffed and equipped by endoscopists
and nurses from the main Telemark centre.
All lesions detected at the screening examinations
were subjected to tissue sampling and histopathologi-
cal diagnosis. For faecal occult blood testing, we used
an immunochemical test (FlexSure OBT, Beckman-
Coulter, Palo Alto, CA, USA).
We defined a positive screening test as any polyp
10mmormoreindiameter,anyhistologicallyverified
adenoma irrespective of size, carcinoma, or a positive
occult blood test. These findings qualified participants
forfullcolonoscopy,whichwasalsodoneatthescreen-
ing centres. At colonoscopy, all polyps 4 mm or more
in diameter were removed by diathermy loop resec-
tion, and hot or cold biopsy forceps were applied to
smaller lesions. Twenty one per cent of people
screened had colonoscopy.
13 We defined screen
detected colorectal cancers as lesions found at flexible
sigmoidoscopy or during work-up colonoscopy of
screen positive participants. After screening and treat-
ment of screen positive participants, follow-up of indi-
vidual participants has been restricted to usual public
healthcare,whichbyandlargeimpliesnosurveillance
within the first five years.
14
Before the start of the study, we established criteria
for exclusion from the screening examination by per-
sonalcontactwiththepeopleinvited.Peoplewhofitted
at least one of the criteria listed below were not
screened but were included in the intention to screen
analyses,assimilarinformationwasnotavailablefrom
thecontrolgroup.Theexclusioncriteriawereprevious
open colorectal surgery, need for long term attention
and nursing services (somatic or psychosocial reasons,
mental retardation), ongoing cytotoxic treatment or
radiotherapyformalignantdisease,severechroniccar-
diac or pulmonary disease (New York Heart Associa-
tion III-IV), lifelong anticoagulant treatment,
admission to hospital for a coronary event during the
previous three months, cerebrovascular accident dur-
ing the previous three months, and residence abroad.
Death or a diagnosis of colorectal cancer before the
study entry date was available through national regis-
tries and was used as a criterion for exclusion from
analyses.
Study entry
The date of entry into the study for the people in the
screening group was the date of the screening appoint-
ment, evenly distributed throughout the two year
screening period (January 1999 to December 2000)
by central, random allocation. For data analyses, com-
puterised random allocation of individual entry dates
within the same two year time period was similarly
Randomised to screening group (n=13 823)
Flexible sigmoidoscopy only (n=6915)
Combined flexible sigmoidoscopy and faecal
  occult blood testing (n=6908)
Randomised to control group (n=41 913)
Attended for
screening (n=8846)
Classified as pre-study
emigrants (updates of
population registry)
(n=21)
Classified as pre-study
emigrants (updates of
population registry)
(n=217)
Eligible for follow-up (n=41 092) Eligible for follow-up (n=13 653)
Excluded (colorectal
cancer or death before
study entry) (n=149)
Excluded (colorectal
cancer or death before
study entry) (n=604)
Did not attend or excluded from screening
(but not from analysis) owing to criteria
for exclusion from examination (n=4828)
People aged 55-64 years in population registry (n=55 736)
Fig 1 | Flow chart for Norwegian Colorectal Cancer Prevention trial 1 cohort screened January
1999 to December 2001
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ple in the control group were assigned an individual
studyentrydate.Peoplewhodevelopedcolorectalcar-
cinomaordiedbeforetheirindividualstudyentrydate
were excluded from analyses in both groups.
Outcomes
The primary end point in the NORCCAP trial 1 is
incidence of colorectal cancer to be reported after 5,
10, and 15 years of follow-up on an intention to screen
basis, in which all randomised, eligible people are
included, regardless of their compliance with the
screening examination. Further end points are mortal-
ity from and incidence of colorectal cancer within the
reach of the flexible sigmoidoscope (rectum and sig-
moid colon) for attenders (per protocol analysis).
Follow-up
We followed people in both groups through national
registries.InNorway,reportingofdataonanyincident
cancer to the cancer registry of Norway and on any
causeofdeathtotheNorwegiancauseofdeathregistry
is compulsory. These registries are virtually 100%
complete.
15 We retrieved all incident cases of colorec-
talcancerinthestudycohortfromthemaindatabaseat
the cancer registry. The end of follow-up for incidence
of colorectal cancer was 31 December 2006. The can-
cerregistryofNorwayusesamodifiedversionofICD-
7 (international classification of diseases, 7th revision)
for coding, in which “localised disease” constitutes
Dukes’ A and B and “advanced disease” constitutes
tumours infiltrating neighbouring organs and Dukes’
C.InformationoncausespecificdeathcameinICD-10
format from the Norwegiancauseof death registry.As
this registry has a one year delay compared with the
cancer registry, end of follow-up for cause specific
death in this paper is 31 December 2005.
This first report from the study came after a mini-
mumoffiveyears’follow-uponcolorectalcancermor-
tality for all people included in the study. As the delay
in registration of the cause of death is one year longer
than the delay in registration of cancer incidence, this
reportcomprisesaminimumofsixyears’follow-upfor
incidence of colorectal cancer. Assessment of both the
cause of death and colorectal cancer staging for the
registries used was blinded to the group status of parti-
cipants in the study.
Sample size
On the basis of data from the cancer registry of Nor-
way, we expected an accumulated five year incidence
of colorectal cancer of approximately 1% (180 cases
per 100000 person years) in the control group at age
60-69 years. Assuming 70% compliance and 50% cov-
erage of the colorectal mucosa by flexible sigmoido-
scopy, we regarded a 30% reduction in incidence
after five years in the intention to screen population
as possible to achieve and definitely worth while to
detect. With a 5% significance level (two sided), we
estimated the power to detect this difference to be
90% if 14000 people were invited for screening and
42000 people were allocated to the control group.
This corresponds to approximately 75% power to
detect a 25% reduction.
Statistical methods
We present results as cumulative incidence rates. In
addition,we illustratetime tocolorectalcancerby esti-
mating the cumulative hazard function, which clearly
shows non-proportionality. We analysed mortality
from colorectal cancer and total mortality by using
Cox proportional hazards model, as proportionality
was not affected by screen detected colorectal cancers.
We used the Nelson-Aalen method to estimate cumu-
lativehazardratesinthescreeningandcontrolgroups.
We censored all time to event data at the end of the
follow-up period and at emigration. Additionally, for
analyses of incidence of colorectal cancer and esti-
mates of cumulative hazard we censored data at death
and at diagnosis of colorectal malignancy other than
adenocarcinoma.
RESULTS
Figure 1 shows the flow chart for the 55736 people
who were randomised. Altogether, 753 cases of color-
ectal cancer or death occurred before the study entry
date, including four people with previous colorectal
cancer who were erroneously screened. This left
13653 people in the screening group and 41092 in
the control group eligible for analyses (fig 1). Censor-
ingowingtoemigrationoccurredfor1196people,and
21peoplewerecensoredasaresultofcolorectalmalig-
nancyotherthancolorectalcarcinoma(13neuroendo-
crine (carcinoid) tumours and eight squamous cell
carcinomas). In the screening group, 459 people were
excluded from examination, according to the
Accumulated cases (accumulated No/1000 people) of colorectal cancer in subsets of screening group and control group
after six to eight years’ follow-up
Screening group (n=13 653)
Control group
(n=41 092)
Attended (n=8846)
*Did not attend
(n=4807) Total Screen detected
Post-screen
detected
Subtotal
attending
Localised colorectal cancer 20 6 26 7 33 (2.4) 62 (1.5)
Advanced colorectal cancer 11 (1.2) 29 (3.3) 40 (4.5) 38 (7.9) 78 (5.7) 262 (6.4)
Stage unspecified 2 3 5 7 12 (0.9) 38 (0.9)
Total 33 38 71 (8.0) 52 (10.8) 123 (9.0) 362 (8.8)
*Includes 459 people excluded from examination (but not from analysis) according to exclusion criteria.
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tion to screen analyses.
The two groups were similar in the distribution of
age (mean 59 years) and sex (50% female in both
groups). Of the 13653 people eligible, 8846 had a
screening examination, giving an attendance rate of
64.8% (67% with exclusion of those not examined
owing to exclusion criteria). Compliance was slightly
higher in women than in men (65.9% (4554/6907) v
62.1% (4292/6916)). The attending and non-attending
groupshadsimilaragedistribution(mean58.4and58.
5 years, with a range of 55-64 for both groups). Mean
insertion of the endoscope was 48.9 (SD=15.7) cm for
menand44.0(14.2)cmforwomen,asmeasuredwitha
straightened endoscope. No severe complications
occurredduringflexiblesigmoidoscopy.Atscreening,
a neoplastic lesion was found in 19% (1685/8846) of
people screened, and 5.0% (440/8846) of attenders
had high risk adenoma (≥10 mm in diameter, high
grade dysplasia or villous components) or invasive
cancer.
13 Out of 33 prevalent colorectal cancers
detected by screening, 17 were in the 6915 people
invited for flexible sigmoidoscopy only (2.5 per 1000
invited) and 16 in the 6908 people invited for com-
bined flexible sigmoidoscopy and faecal occult blood
testing (2.3 per 1000 invited).
The compliance for colonoscopy work-up was 97%
(1812/1872). Ninety per cent (1617/1812) of colonos-
copies took place without sedation or analgesia. The
rate of caecal intubation at first attempt was 89%
(1623/1812). In the 189 patients in whom baseline
colonoscopywork-upwasinitiallyincomplete,thecae-
cum was reached in 12 on a second attempt, double
contrast barium enema was done in 52, and six were
referred directly to surgery owing to distal tumour.
Thus, 70 patients had their entirecolon visualised dur-
ing work-up or post-surgical surveillance. In the
remaining 119 people with incomplete visualisation
of the caecum, none had incident colorectal cancer at
six to eight year follow-up. In addition to people with
neoplasia at flexible sigmoidoscopy, colonoscopy
work-upwasdonein349patientsbecauseofapositive
faecal occult blood test (n=150), symptoms (n=65,
including one case of colorectal carcinoma), hyper-
plastic polyp >10 mm (n=28), poor bowel cleansing
at flexible sigmoidoscopy (n=24), tissue sample lost at
screening (n=22), and other reasons (n=60).
Median follow-up after inclusion in the trial was
seven (range six to eight) years for incident colorectal
cancer and six (range five to seven) years for mortality
from colorectal cancer. The cumulative hazard rate
starts at a high level in the screening group owing to
detectionofprevalentcolorectalcancercasesatscreen-
ing (fig 2). We found no difference in the cumulative
hazard of colorectal cancer between the screening
group and the control group (intention to screen ana-
lysis; 134.5 v 131.9 cases per 100000 person years).
The accumulated number of colorectal cancers after
six to eight years of follow-up was 123 in the screening
group, including 33 screen detected tumours, and 362
in the control group (table). In the two screening
groups, 54 accumulated colorectal cancers occurred
in the flexible sigmoidoscopy group (7.9 per 1000)
and 69 (10.1 per 1000) in the group invited to com-
bined flexible sigmoidoscopy and faecal occult blood
testing.Whenwerestrictedthecumulativehazardplot
to attenders and rectosigmoidal cancers only, the line
crossesthatofthecontrolgroup,suggestinganeffectof
polypectomy for left sided colorectal cancer in those
attending for screening (fig 3). The cumulative inci-
dence of rectosigmoidal cancer was 35 cases in 8846
attenders (58 per 100000 person years) and 217 in
41092 controls (79 per 100000 person years)
(P=0.103). Of 90 post-screen incident colorectal can-
cers in the screening group, 37 appeared among 6915
peopleinvitedforflexiblesigmoidoscopyonly(5.4per
1000) compared with 53 in 6908 people invited for
combined flexible sigmoidoscopy and faecal occult
blood testing (7.7 per 1000).
Atotalof24of13653peoplein thescreeninggroup
and 99 of 41092 in the control group died from color-
ectal cancer during follow-up. In the screening group
as a whole (intention to screen), total mortality was
reduced by 27% (hazard ratio 0.73, 95% confidence
interval 0.47 to 1.13, P=0.16) for colorectal cancer
and by 37% (0.63, 0.34 to 1.18, P=0.15) for recto-
sigmoidal cancer compared with the control group.
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Fig 2 | Cumulative hazard for colorectal cancer in screening
and control groups
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Fig 3 | Cumulative hazard for rectosigmoidal cancer among
attenders compared with control group
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reduced by 59% (hazard ratio 0.41, 0.21 to 0.82,
P=0.011) for colorectal cancer and by 76% (0.24, 0.08
to0.76, P=0.016) forrectosigmoidal cancer;thiscorre-
sponded to three and 57 deaths from rectosigmoidal
cancer.Allcausemortalitywassimilarinthescreening
groupand the controlgroup(hazardratio1.02, 0.98 to
1.07, P=0.28).
We found a more favourable stage distribution for
patients with screen detected colorectal cancer
compared with those in the control group and the
non-attending group (table). Almost half of the total
number of colorectal cancers among attenders
(33/71) were screen detected tumours, and 27 of the
38 post-screen colorectal cancers were localised
proximal to the rectum and sigmoid colon. In atten-
ders, 36 of 71 colorectal cancers were localised
proximal to the rectosigmoid colon (4.07/1000
attenders) compared with 145 of 362 in the control
group (3.53/1000 people, 3.74/1000 if nine tumours
with undefined localisation were to be classified as
proximal). Case fatalities from colorectal cancer
diagnosed within the update period of cause of death
registrations (that is, including 2005) were 9/66 (14%)
in the group of attenders (2/33 (6%) screen detected)
compared with 15/38 (39%) among non-attendersand
99/308 (32%) in the control group. Excluding screen
detected colorectal cancers, deaths from post-screen
detected colorectal cancer among attenders (“interval
cancers”) were 7/33 (21%).
DISCUSSION
This study showed a non-significant reduction in mor-
talityof27%fromtotalcolorectalcancerand37%from
rectosigmoidal cancer by intention to screen analysis
and no reduction in accumulated incidence of color-
ectal cancer after seven years of follow-up. Among
attenders, per protocol analysis (an analysis prone to
selection bias) showed a significant 59% reduction in
incidence of total colorectal cancer and 76% reduced
incidence of rectosigmoidoal cancer.
Reduction in mortality is the ultimate aim for any
cancer screening programme. Endoscopic screening
for colorectal neoplasia has the unique potential to go
beyond that—to prevent colorectal cancer from devel-
oping by detection and removal of colorectal cancer
precursor lesions (polypectomy of adenomas).
Amongseveralscreeningtrialsexploringthispotential
with flexible sigmoidoscopy, the Norwegian Colorec-
tal CancerPreventiontrial1 is the only trialwith a one
stage invitation design mimicking a national screening
programme.
1216-18
Is it too early to see an effect in intention to screen
analyses?
The flat incidence curve for rectosigmoidal cancer in
attenders (fig 3) illustrates that attendance for flexible
sigmoidoscopy screening is associated with a reduced
risk of post-screening rectosigmoidal cancer, whether
this is due to self selection of people at low risk choos-
ing to attend, a high screening detection rate for
established but asymptomatic cancers, or a genuine
effect of polypectomy in preventing cancer. Attenders
intheNORCCAPtrial1weremoreoftensmokersbut
had a modestly lower risk profile, as judged by dietary
habits and physical exercise, compared with the con-
trol group.
19 Thus, a major “healthy screenee” effect
does not seem to be occurring in this study.
We found a trend towards reduced mortality from
colorectal cancer for both total colorectal cancer mor-
tality (27% reduction) and rectosigmoidal cancer mor-
tality (37%), but this was not statistically significant in
intention to screen analysis, the single most important
analysisfromapublichealthperspective.Correspond-
ing reductions in mortality among attenderswere 59%
and 76%, both statistically significant compared with
the control group. When evaluating the latter result,
one should bear in mind the inherent risk of selection
bias in looking at attenders only.
Two main possibilities could explain the limited
effect of screening with flexible sigmoidoscopy in this
study: either the method is not effective in reducing
incidence of colorectal cancer or the lag period for
the development of cancer from precursor lesions is
considerably longer than is commonly assumed. The
second possibility is more likely, as Cuzick and associ-
atespointedout.
20Contaminationofthecontrolgroup
with colonoscopy is not a likely explanation for our
findings, as no organised screening for colorectal can-
cer occurs in Norway and opportunistic screening is
limited. According to an unpublished survey by GH
in 2006, less than 5% of colonoscopies in Norway are
related to colorectal cancer screening activity com-
pared with 50% in the United States.
21
How to evaluate with a high proportion of prevalent,
screen detected cancers
Prevalent (screen detected) colorectal cancers will
dilute any incidence reducing effect of polypectomy.
Thiseffecthasbeenestimatedtolastfortwoyearsafter
screening,
22 but looking at results from the NORC-
CAP trial 1, it may last considerably longer than anti-
cipated. Selectively excluding prevalent screen
detected colorectal cancers from the analysis would
giveanapparentlyhighlysignificanteffectofscreening
with flexible sigmoidoscopy in reducing the incidence
of rectosigmoidal cancer for people who attend, but
this leads to severe bias. As the similar group of preva-
lent cancer cases cannot be identified and excluded
from the control group, this type of analysis would
overestimate the screening effect of flexible sigmoido-
scopy. We have therefore chosen to base our conclu-
sions on cumulative incidence. As flexible
sigmoidoscopy screening showed no effect on total
incidence of or mortality from colorectal cancer in
the intention to screen analyses at this stage of follow-
up,we didnot doa separate analysisofthe two screen-
ing modalities (flexible sigmoidoscopy and combined
flexible sigmoidoscopy and faecal occult blood test).
However,outof13casesofcolorectalcancersubjected
to both screening modalities, three were detected
RESEARCH
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ible sigmoidoscopy was negative.
Previous case-control and observational studies, as
well as a small scale randomised trial, have indicated
thatendoscopicscreeningmayreducetheincidenceof
colorectal cancer by 50-90%.
5-79 Our results, with 33
screen detected cases of colorectal cancer and 38
cases of cancer diagnosed during the seven year post-
screening period, indicate that screening with flexible
sigmoidoscopy may detect close to 50% of neoplastic
lesionsalreadymalignantordestinedtoturnmalignant
within a seven year timeframe. This is consistent with
estimatesfromDanishandCanadianstudies.
2324Some
differences exist in diagnostic yield between ongoing
studies of screening with flexible sigmoidoscopy. The
pick-up rates for both any neoplasia (19%) and
advanced neoplasia (5%) in our study were higher
than or comparable to those in the ongoing British
(12% and 5%) and Italian (12% and 3.4%) flexible sig-
moidoscopy screening trials—all in 55-64 year age
groups.
131617 As we cannot yet foresee the outcome of
a “once only” flexible sigmoidoscopy screening con-
cept in terms of prevention of colorectal cancer, it
will be very interesting to follow all these studies with
their differences in baseline pick-up rates and polyp
size dependent thresholds for a work-up colonoscopy.
Afterall,mostadenomasregressordonotdevelopinto
cancers,andnewadenomasmayappearaskeyplayers
beforethe“onceonly”flexiblesigmoidoscopyhashad
time to show an effect.
“Interval cancers” fared no worse than cancer cases in
controls
The apparent reduction in deaths from colorectal can-
cer in people with screen detected cancers in the
screening group (6% colorectal cancer fatalities
compared with 32% among controls) may be due to a
morefavourablestagedistribution,butleadtimebiasis
necessarily also an important factor that precludes for-
mal comparison and valid conclusions. We were reas-
sured to see that people with colorectal cancer that
appeared after negative screening results fared no
worse than those in the control group (21% and 32%
of patients with colorectal cancer died from their can-
cer in the two groups). This suggests that length time
bias (that is, the fast growing, aggressive tumours not
beingpickedupbyscreening)maynotbeaproblemin
this study.
From a public health perspective, our results indi-
cate that screening with flexible sigmoidoscopy may
not reduce the overall incidence of colorectal cancer
to the extent and within the timeframe expected at a
populationlevel,butitseemstobepromisingforredu-
cing the incidence of rectosigmoidal cancer among
attenders. The results also indicate a need to look into
alternative screening modalities to be tested in rando-
mised trials without waiting for further follow-up
results of this trial or other ongoing trials on screening
with flexible sigmoidoscopy.
16-18 Although recom-
mended for several years and launched as national
screening programmes in several countries, screening
with colonoscopy has not yet been subjected to ade-
quately designed randomised trials. Our findings on
polypectomy for prevention of colorectal cancer may
not automatically be extrapolated from the recto-
sigmoidal segment and flexible sigmoidoscopy to the
entire colon and colonoscopy, as the risk profiles and
natural course may bequite different forproximaland
distal colorectal cancers. The findings may, however,
contribute to adequate design of randomised trials on
screening with colonoscopy, including estimates of
sample size and follow-up and sufficient awareness of
theanalyticalproblemscausedbyahighproportionof
screen detected, prevalent colorectal cancers.
Conclusions
This seven year post-screening analysis indicates that
theeffectofscreeningwithflexiblesigmoidoscopyand
polypectomy on reducing the incidence of colorectal
cancermaybelowerandwillcertainlyoccurlaterthan
anticipated. At this stage of follow-up, a large propor-
tion of prevalent, screen detected colorectal cancers
makes it uncertain whether the observed flattening of
the incidence curve during the first years after screen-
ing is simply due to prevalent, screen detected color-
ectal cancers that would otherwise have appeared as
incident colorectal cancers or a genuine preventive
effect on colorectal cancer by removal of adenomas.
The findings, however, suggest an incidence reducing
effect on distal colorectal cancer, matched by a 76%
reduction in mortality for people attending screening.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Screening for colorectal cancer by endoscopy (flexible
sigmoidoscopy and colonoscopy) has been advocated and
implemented in several countries without previous
randomised trials
Screening for faecal occult blood is a poor method for
detectionofcolorectalcancerprecursorlesions(adenomas)
compared with endoscopy
Quantification of the effects of endoscopic screening has
not been investigated through randomised trials
WHAT THIS STUDY ADDS
A non-significant reduction in mortality from colorectal
cancer after six years of follow-up was seen in intention to
screen analysis
The accumulated incidence rates of colorectal cancer were
similar in the screening and the control groups, suggesting
that seven years’ follow-up may be too early to see any
reduction in incidence
Theriskofmortalityfromcolorectalcancerforattenderswas
less than half that seen in controls; it was smaller for
rectosigmoidal cancer than for all colorectal cancers
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All participants in the screening group have been informed about the
nature and purpose of the study, and all those who attended screening
provided written informed consent in advance.
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